The diagnosis of polycythemia vera: New tests and old dictums

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 3, 2006, Pages 455-469

  Tefferi, Ayalew ^a  

^a Mayo Clinic   (United States)

Author keywords

bone marrow; diagnosis; erythropoietin; polycythemia; red cell mass

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; VON HIPPEL LINDAU PROTEIN;

ALGORITHM; BONE MARROW EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ERYTHROCYTOSIS; GENE MUTATION; HEALTH CARE COST; HEMATOCRIT; HISTOPATHOLOGY; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; PATHOGENESIS; PLASMA VOLUME; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; BONE MARROW; DIAGNOSIS, DIFFERENTIAL; ERYTHROCYTE VOLUME; ERYTHROPOIETIN; HUMANS; POLYCYTHEMIA VERA;

EID: 33744966375     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.07.005     Document Type: Review

References (121)

1. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clinic Proceedings 78 (2003) 174-194
2. Passamonti F., Rumi E., Pungolino E., et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. American Journal of Medical 117 (2004) 755-761
3. Chievitz E., and Thiede T. Complications and causes of death in polycythemia vera. Acta Medica Scandinavica 172 (1962) 513-523
4. Berk P.D., Wasserman L.R., Fruchtman S.M., and Goldberg J.D. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman L.R., et al. (Ed). Polycyhtemia Vera and the Myeloproliferative Disorders (1995), W. B. Saunders, London 166-194
5. Landolfi R., Marchioli R., Kutti J., et al. Efficacy and safety of low-dose aspirin in polycythemia vera. The New England Journal of Medicine 350 (2004) 114-124
6. Streiff M.B., Smith B., and Spivak J.L. The diagnosis and management of polycythemia vera in the era since the polycythemia vera study group: a survey of american society of hematology members' practice patterns. Blood 99 (2002) 1144-1149
7. Andreasson B., Lofvenberg E., and Westin J. Management of patients with polycythaemia vera: results of a survey among Swedish haematologists. European Journal Haematology 74 (2005) 489-495
8. Isbister J.P. The contracted plasma volume syndromes (relative polycythaemias) and their haemorheological significance. Baillieres Clinic Haematology 1 (1987) 665-693
9. Schwarcz T.H., Hogan L.A., Endean E.D., et al. Thromboembolic complications of polycythemia: polycythemia vera versus smokers' polycythemia. Journal of Vascular Surgery 17 (1993) 518-522
10. Ammash N., and Warnes C.A. Cerebrovascular events in adult patients with cyanotic congenital heart disease. Journal of the American College Cardiology 28 (1996) 768-772
11. Fisher M.J., Prchal J.F., Prchal J.T., and AD D.A. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 84 (1994) 1982-1991
12. Le Couedic J.P., Mitjavila M.T., Villeval J.L., et al. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood 87 (1996) 1502-1511
13. Means Jr. R.T., Krantz S.B., Sawyer S.T., and Gilbert H.S. Erythropoietin receptors in polycythemia vera. Journal of Clinical Investigation 84 (1989) 1340-1344
14. Ang S.O., Chen H., Hirota K., et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nature Genetics 32 (2002) 614-621
15. Moo-Penn W.F., Schneider R.G., Shih T., et al. Hemoglobin Ohio (beta 142 Ala replaced by): a new abnormal hemoglobin with high oxygen affinity and erythrocytosis. Blood 56 (1980) 246-250
16. Hoyer J.D., Allen S.L., Beutler E., et al. Erythrocytosis due to bisphosphoglycerate mutase deficiency with concurrent glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. American Journal of Hematology 75 (2004) 205-208
17. Sokol L., Luhovy M., Guan Y., et al. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood 86 (1995) 15-22
18. Tyndall M.R., Teitel D.F., Lutin W.A., et al. Serum erythropoietin levels in patients with congenital heart disease. The Journal of Pediatrics 110 (1987) 538-544
19. Milledge J.S., and Cotes P.M. Serum erythropoietin in humans at high altitude and its relation to plasma renin. Journal of Applied Physiology 59 (1985) 360-364
20. DiMarco A.T. Carbon monoxide poisoning presenting as polycythemia. The New England Journal of Medicine 319 (1988) 874
21. Coulthard M.G., and Lamb W.H. Polycythaemia and hypertension caused by renal artery stenosis. Archives of Disease in Childhood 86 (2002) 307-308
22. Tanabe N., Ohnishi K., Fukui H., and Ohno R. Effect of smoking on the serum concentration of erythropoietin and granulocyte-colony stimulating factor. Internal Medicine 36 (1997) 680-684
23. Hoffstein V., Herridge M., Mateika S., et al. Hematocrit levels in sleep apnea. Chest 106 (1994) 787-791
24. Samyn I., Fontaine C., Van Tussenbroek F., et al. Paraneoplastic syndromes in cancer: Case 1. Polycythemia as a result of ectopic erythropoietin production in metastatic pancreatic carcinoid tumor. Journal of Clinical Oncology 22 (2004) 2240-2242
25. Drenou B., Le Tulzo Y., Caulet-Maugendre S., et al. Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Nouvelle Revue française d'Hématologie 37 (1995) 197-199
26. Rhoden E.L., and Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. The New England Journal of Medicine 350 (2004) 482-492
27. Jelkmann W. Erythropoietin. Journal of Endocrinological Investigation 26 (2003) 832-837
28. Pearson T.C., and Messinezy M. Idiopathic erythrocytosis, diagnosis and clinical management. Pathologie Biologie (Paris) 49 (2001) 170-177
29. Blacklock H.A., and Royle G.A. Idiopathic erythrocytosis-a declining entity. British Journali of Haematology 115 (2001) 774-781
30. Fairbanks V.F., and Tefferi A. Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to apparent polycythemia. European Journal of Haematology 65 (2000) 285-296
31. Fairbanks V.F. Myeloproliferative disease: polycythemia vera: the packed cell volume and the curious logic of the red cell mass. Hematology 4 (2000) 381-395
32. Brown S.M., Gilbert H.S., Krauss S., et al. Spurious (relative) polycythemia: A non-existent disease. American Journal of Medicine 50 (1971) 220-227
33. Fessel W.J. Odd men out: individuals with extreme values. Archives of Internal Medicine 115 (1965) 736-737
34. Fairbanks V.F., Klee G.G., Wiseman G.A., et al. Measurement of blood volume and red cell mass-re-examination of Cr-51 and I-125 methods (corrected version of Vc666). Blood Cells Molecules and Diseases 22 (1996) 169-186
35. Geisbock F. Die Bedeutung der Blutdruckmessung fur die Praxis. Archives Clinical Medicine (Leipzig) 83 (1905)
36. Lawrence J.H., and Berlin N.I. Relative polycythemia-the polycythemia of stress. The Yale Journal of Biology and Medicine 24 (1952) 498-505
37. Bentley S.A., and Lewis S.M. The relationship between total red cell volume, plasma volume and venous haematocrit. British Journali of Haematology 33 (1976) 301-307
38. Burge P.S., Johnson W.S., and Prankerd T.A. Morbidity and mortality in pseudopolycythaemia. Lancet 1 (1975) 1266-1269
39. Jonsson V., Bock J.E., and Nielsen J.B. Significance of plasma skimming and plasma volume expansion. Journal of Applied Physiology 72 (1992) 2047-2051
40. Hering E. Versuche, die Schnelligkeit des Blutlaufs und der Absonderung zu Bestimmen. The Journal of Physiology 3 (1829) 85-126
41. Stewart G.N. Researches on the circulation time and on the influences which affect it IV. The output of the heart. The Journal of Physiology 22 (1897)
42. Keith N.M., Rowntree L.G., and Geraghty J.T. A method for the determination of plasma and blood volume. Archives of Internal Medicine xvi (1915) 547-557
43. Hamilton W.F., Moore J.W., Kinsman J.M., and Spurling R.G. Simultaneous detrmination of the pulmonary and systemic circulation times in man and of a figure related to cardiac output. American Journal of Physiology 84 (1928) 338-344
44. Rowntree L.G., Brown G.E., and Roth G.M. Volume of Blood and Plasma in Health and Disease (1929), W B Saunders, London
45. Wright R.R., Tono M., and Pollycove M. Blood volume. Seminars in Nuclear Medicine 5 (1975) 63-78
46. Pearson T.C., Guthrie D.L., Simpson J., et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. British Journal of Haematology 89 (1995) 748-756
47. Standard techniques for the measurement of red-cell and plasma volume. A report by the international committee for standardization in hematology (ICSH): panel on diagnostic applications of radioisotopes in haematology. British Journal of Haematology 25 (1973) 801-814
48. Balga I., Solenthaler M., and Furlan M. Should whole-body red cell mass be measured or calculated?. Blood Cells Molecules and Diseases 26 (2000) 25-31 [discussion 32-26]
49. Fairbanks V.F. Commentary: should whole-body red cell mass be measured or calculated. Blood Cells Molecules and Diseases 26 (2000) 32-36
50. Hlad Jr. C.J., and Tanz R. An analysis of technical errors in radioalbumin blood volume methods and presentation of a modified method. Journal of Laboratory and Clinical Medicine 52 (1958) 289-298
51. Hinghofer-Szalkay H., and Greenleaf J.E. Continuous monitoring of blood volume changes in humans. Journal of Applied Physiology 63 (1987) 1003-1007
52. Leslie W.D., Dupont J.O., and Peterdy A.E. Effect of obesity on red cell mass results. The Journal of Nuclear Medicine 40 (1999) 422-428
53. Wasserman L.R. The treatment of polycythemia. A panel discussion. Blood 32 (1968) 483-487
54. Shih L.Y., Lee C.T., and Ou Y.C. Prediction of clinical course in patients with idiopathic erythrocytosis by endogenous erythroid colony assay but not by serum erythropoietin levels. Experimental Hematology 25 (1997) 288-292
55. Adamson J.W., Fialkow P.J., Murphy S., et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. The New England Journal of Medicine 295 (1976) 913-916
56. Thiele J., Kvasnicka H.M., Muehlhausen K., et al. Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients. Pathol Res Pract 197 (2001) 77-84
57. Temerinac S., Klippel S., Strunck E., et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95 (2000) 2569-2576
58. Bettinotti M.P., Olsen A., and Stroncek D. The use of bioinformatics to identify the genomic structure of the gene that encodes neutrophil antigen NB1, CD177. Clinical Immunology 102 (2002) 138-144
59. Teofili L., Martini M., Luongo M., et al. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. Journal of Clinical Oncology 20 (2002) 4249-4254
60. Bodni R.A., Sapia S., Galeano A., and Kaminsky A. Indolent systemic mast cell disease: immunophenotypic characterization of bone marrow mast cells by flow cytometry. Journal of the European Academy of Dermatology Venereology 17 (2003) 160-166
61. Griesshammer M., Klippel S., Strunck E., et al. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Annals of Hematology 83 (2004) 364-370
62. Klippel S., Strunck E., Temerinac S., et al. Quantification of PRV-1 mRNA distinguishes Polycythemia vera from secondary erythrocytosis. Blood 102 (2003) 3569-3574
63. Kralovics R., Buser A.S., Teo S.S., et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 102 (2003) 1869-1871
64. Alcocer L. Statins for everybody? New evidence on the efficacy and safety of the inhibitors of HMG Co-A reductase. American Journal of Therapeutics 10 (2003) 423-428
65. Cilloni D., Carturan S., Gottardi E., et al. Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients. Blood 103 (2004) 2428 [author reply 2429]
66. Florensa L., Besses C., Zamora L., et al. Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia. Blood 103 (2004) 2427-2428
67. Passamonti F., Pietra D., Malabarba L., et al. Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. British Journal of Haematology 126 (2004) 650-656
68. Zhang J., Pellagatti A., Campbell L., et al. Neutrophil PRV-1 gene expression in myeloproliferative, myelodysplastic and reactive blood disorders. British Journal of Haematology 125 (2004) 17
69. Tanaka C., Kuruma I., and Kuramoto A. Histochemical demonstration of 5-hydroxytryptamine in platelets and megakaryocytes. Blood 30 (1967) 54-61
70. Tranzer J.P., Prada M.d., and Pletscher A. Storage of 5-hydroxytryptamine in megakaryocytes. The Journal of Cell Biology 52 (1972) 191-197
71. Pareti F.I., Gugliotta L., Mannucci L., et al. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thrombosis and Haemostasis 47 (1982) 84-89
72. Chauveau J., Fert V., Morel A.M., and Delaage M.A. Rapid and specific enzyme immunoassay of serotonin. Clinical Chemistry 37 (1991) 1178-1184
73. Maurer-Spurej E., Dyker K., Gahl W.A., and Devine D.V. A novel immunocytochemical assay for the detection of serotonin in platelets. British Journal of Haematology 116 (2002) 604-611
74. Zerbinati P., Randi M.L., Rossi C., et al. Two methods for intraplatelet serotonin evaluation-their use in thrombocytosis. Clin Appl Thromb Hemost 3 (1997) 144-146
75. Fabris F., Randi M.L., Casonato A., et al. Clinical significance of beta-thromboglobulin in patients with high platelet count. Acta Haematologica 71 (1984) 32-38
76. Koch C.A., Lasho T.L., and Tefferi A. Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. British Journal of Haematology 127 (2004) 34-39
77. Reid C.D. The significance of endogenous erythroid colonies (EEC) in haematological disorders. Blood Reviews 1 (1987) 133-140
78. Prchal J.F., and Axelrad A.A. Letter: Bone-marrow responses in polycythemia vera. The New England Journal of Medicine 290 (1974) 1382
79. Juvonen E., Partanen S., and Ruutu T. Colony formation by megakaryocytic progenitors in essential thrombocythaemia. British Journal of Haematology 66 (1987) 161-164
80. Zwicky C., Theiler L., Zbaren K., et al. The predictive value of clonogenic stem cell assays for the diagnosis of polycythaemia vera. British Journal of Haematology 117 (2002) 598-604
81. Partanen S., Juvonen E., Ikkala E., and Ruutu T. Spontaneous erythroid colony formation in the differential diagnosis of erythrocytosis. European Journal of Haematology 42 (1989) 327-330
82. Dobo I., Donnard M., Girodon F., et al. Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera. The Hematology Journal 5 (2004) 161-167
83. Shih L.Y., Lee C.T., See L.C., et al. In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia. European Journal of Clinical Investigation 28 (1998) 569-576
84. Dobo I., Mossuz P., Campos L., et al. Comparison of four serum-free, cytokine-free media for analysis of endogenous erythroid colony growth in polycythemia vera and essential thrombocythemia. The Hematology Journal 2 (2001) 396-403
85. Horikawa Y., Matsumura I., Hashimoto K., et al. Markedly reduced expression of platelet C-Mpl receptor in essential thrombocythemia. Blood 90 (1997) 4031-4038
86. Moliterno A.R., Hankins W.D., and Spivak J.L. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. The New England Journal of Medicine 338 (1998) 572-580
87. Yoon S.Y., Li C.Y., and Tefferi A. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. European Journal of Haematology 65 (2000) 170-174
88. Le Blanc K., Andersson P., and Samuelsson J. Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera. British Journal of Haematology 108 (2000) 80-85
89. Tefferi A., Yoon S.Y., and Li C.Y. Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood 96 (2000) 771-772
90. Duensing S., Duensing A., Meran J.G., et al. Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders. Molecular Pharmacology 52 (1999) 146-150
91. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
92. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature, in press.
93. Kralovics R., Passamonti F., Buser A.S., et al. A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. The New England Journal of Medicine 352 (2005) 1779-1790
94. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
95. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK2 mutation in polycythemia vera. The Journal of Biological Chemistry (2005)
96. Steensma D.P., Dewald G.W., Lasho T.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both Atypical myeloproliferative disorders and the myelodysplastic syndrome. Blood (2005) 10.1182/blood-2005-03-1183 [Blood First Edition Paper, prepublished online April 28, 2005]
97. Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood (2005) 10.1182/blood-2005-03-1320 [Blood First Edition Paper, prepublished online May 26, 2005]
98. Lamy T., Devillers A., Bernard M., et al. Inapparent polycythemia vera-an unrecognized diagnosis. American Journal of Medicine 102 (1997) 14-20
99. Messinezy M., Westwood N.B., El-Hemaidi I., et al. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. British Journal of Haematology 117 (2002) 47-53
100. Mossuz P., Girodon F., Donnard M., et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 89 (2004) 1194-1198
101. Diez-Martin J.L., Graham D.L., Petitt R.M., and Dewald G.W. Chromosome studies in 104 patients with polycythemia vera. Mayo Clinic Proceedings 66 (1991) 287-299
102. Andreasson B, Löfvenberg E, Westin J. Management of patients with polycythaemia vera: Results of a survey among Swedish haematologists. European Journal of Haematology, in press, available online.
103. Galacteros F., Rosa R., Prehu M.O., et al. Diphosphoglyceromutase deficiency: new cases associated with erythrocytosis. Nouvelle Revue française d'Hématologie 26 (1984) 69-74
104. Gordeuk V.R., Stockton D.W., and Prchal J.T. Congenital polycythemias/erythrocytoses. Haematologica 90 (2005) 109-116
105. Cario H. Childhood polycythemias/erythrocytoses: classification, diagnosis, clinical presentation, and treatment. Annals of Hematology (2004)
106. Vanuxem D., Guillot C., Fornaris E., et al. Secondary polycythaemia in chronic respiratory insufficiency. Thorax 32 (1977) 317-321
107. Smith J.R., and Landaw S.A. Smokers' polycythemia. The New England Journal of Medicine 298 (1978) 6-10
108. Hudgson P., Pearce J.M., and Yeates W.K. Renal artery stenosis with hypertension and high haematocrit. British Medical Journal 1 (1967) 18-21
109. Matsuyama M., Yamazaki O., Horii K., et al. Erythrocytosis caused by an erythropoietin-producing hepatocellular carcinoma. Journal of Surgical Oncology 75 (2000) 197-202
110. Ndububa D.A., Ojo O.S., Adetiloye V.A., et al. The incidence and characteristics of some paraneoplastic syndromes of hepatocellular carcinoma in Nigerian patients. European Journal of Gastroenterol and Hepatology 11 (1999) 1401-1404
111. Wiesener M.S., Seyfarth M., Warnecke C., et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 99 (2002) 3562-3565
112. Skultety F.M., Sorrell M.F., and Burklund C.W. Hemangioblastoma of the cerebellum associated with erythrocytosis and an unusual blood supply. Case report. Journal of Neurosurgery 32 (1970) 700-705
113. Weinstein R.S. Parathyroid carcinoma associated with polycythemia vera. Bone 12 (1991) 237-239
114. Suzuki M., Takamizawa S., Nomaguchi K., et al. Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis. British Journal of Haematology 113 (2001) 49-51
115. Jermanovich N.B. Polycystic kidney disease and polycythemia vera. Occurrence in a patient receiving hemodialysis. Archives of Internal Medicine 143 (1983) 1822-1823
116. Bruneval P., Sassy C., Mayeux P., et al. Erythropoietin synthesis by tumor cells in a case of meningioma associated with erythrocytosis. Blood 81 (1993) 1593-1597
117. Spivak J.L. Erythropoietin use and abuse: When physiology and pharmacology collide. Advances in Experimental Medicine and Biology 502 (2001) 207-224
118. Dickerman R.D., Pertusi R., Zachariah N.Y., and Schaller F. Androgen-induced erythrocytosis. American Journal of Hematology 59 (1998) 263-264
119. Wickre C.G., Norman D.J., Bennison A., et al. Postrenal transplant erythrocytosis: a review of 53 patients. Kidney International 23 (1983) 731-737
120. Glicklich D., Kapoian T., Mian H., et al. Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis. Transplantation 68 (1999) 62-66
121. Mrug M., Julian B.A., and Prchal J.T. Angiotensin II receptor type 1 expression in erythroid progenitors: implications for the pathogenesis of postrenal transplant erythrocytosis. Seminars in Nephrology 24 (2004) 120-130